JP2014518624A - ニューログラニン診断キットのためのアッセイ試薬 - Google Patents

ニューログラニン診断キットのためのアッセイ試薬 Download PDF

Info

Publication number
JP2014518624A
JP2014518624A JP2014510535A JP2014510535A JP2014518624A JP 2014518624 A JP2014518624 A JP 2014518624A JP 2014510535 A JP2014510535 A JP 2014510535A JP 2014510535 A JP2014510535 A JP 2014510535A JP 2014518624 A JP2014518624 A JP 2014518624A
Authority
JP
Japan
Prior art keywords
fragment
neurogranin
antibody
aptamer
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014510535A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014518624A5 (enExample
Inventor
アレン デイル エヴェレット
ジュン ヤン
ゾンミン フー
Original Assignee
ザ・ジョンズ・ホプキンス・ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ジョンズ・ホプキンス・ユニバーシティー filed Critical ザ・ジョンズ・ホプキンス・ユニバーシティー
Publication of JP2014518624A publication Critical patent/JP2014518624A/ja
Publication of JP2014518624A5 publication Critical patent/JP2014518624A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
JP2014510535A 2011-05-12 2012-05-14 ニューログラニン診断キットのためのアッセイ試薬 Pending JP2014518624A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161485375P 2011-05-12 2011-05-12
US61/485,375 2011-05-12
PCT/US2012/037774 WO2012155134A2 (en) 2011-05-12 2012-05-14 Assay reagents for a neurogranin diagnostic kit

Publications (2)

Publication Number Publication Date
JP2014518624A true JP2014518624A (ja) 2014-08-07
JP2014518624A5 JP2014518624A5 (enExample) 2015-07-02

Family

ID=47140053

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014510535A Pending JP2014518624A (ja) 2011-05-12 2012-05-14 ニューログラニン診断キットのためのアッセイ試薬

Country Status (4)

Country Link
US (3) US20140141458A1 (enExample)
EP (1) EP2707389B1 (enExample)
JP (1) JP2014518624A (enExample)
WO (1) WO2012155134A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017529527A (ja) * 2014-08-26 2017-10-05 イマビオテクＩｍａｂｉｏｔｅｃｈ 質量分析イメージングによってサンプルを特徴づける方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012051519A2 (en) * 2010-10-14 2012-04-19 The Johns Hopkins University Biomarkers of brain injury
WO2012155134A2 (en) 2011-05-12 2012-11-15 The Johns Hopkins University Assay reagents for a neurogranin diagnostic kit
US9709573B2 (en) 2012-03-13 2017-07-18 The Johns Hopkins University Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration
US20160130585A1 (en) 2013-05-28 2016-05-12 The Johns Hopkins University Aptamers for the treatment of sickle cell disease
EP3022322A4 (en) * 2013-07-17 2017-05-17 The Johns Hopkins University A multi-protein biomarker assay for brain injury detection and outcome
EP3242134A1 (en) 2016-05-04 2017-11-08 Euroimmun Medizinische Labordiagnostika AG Assay for the diagnosis of a neurological disease
US11709168B2 (en) * 2017-05-23 2023-07-25 Brainbox Solutions, Inc. Biomarker levels and neuroimaging for detecting, monitoring and treating brain injury or trauma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008504032A (ja) * 2004-06-25 2008-02-14 ワシントン・ユニバーシティ 脳損傷に対するマーカー

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
SE462454B (sv) 1988-11-10 1990-06-25 Pharmacia Ab Maetyta foer anvaendning i biosensorer
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
ATE160821T1 (de) 1990-06-11 1997-12-15 Nexstar Pharmaceuticals Inc Nukleinsäureliganden
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
NZ267842A (en) 1993-05-28 1997-09-22 Baylor College Medicine Apparatus for measuring molecular mass (by mass spectrometry) in which the sample is ionised on the sample holder and desorbed therefrom by laser pulses
US5866434A (en) 1994-12-08 1999-02-02 Meso Scale Technology Graphitic nanotubes in luminescence assays
US6673533B1 (en) 1995-03-10 2004-01-06 Meso Scale Technologies, Llc. Multi-array multi-specific electrochemiluminescence testing
US6207369B1 (en) 1995-03-10 2001-03-27 Meso Scale Technologies, Llc Multi-array, multi-specific electrochemiluminescence testing
BR9607193B1 (pt) 1995-03-10 2009-01-13 teste de eletroquimioluscÊncia multi-especÍfico de méltiplos conjuntos.
US6140045A (en) 1995-03-10 2000-10-31 Meso Scale Technologies Multi-array, multi-specific electrochemiluminescence testing
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6319670B1 (en) 1995-05-09 2001-11-20 Meso Scale Technology Llp Methods and apparatus for improved luminescence assays using microparticles
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US6413783B1 (en) 1997-09-18 2002-07-02 Meso Scale Technologies, Llc Assay sonication apparatus and methodology
CA2323638A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6780606B1 (en) 1999-02-26 2004-08-24 Synx Pharma, Inc. Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
WO2000056934A1 (en) 1999-03-24 2000-09-28 Packard Bioscience Company Continuous porous matrix arrays
AU2001291217A1 (en) 2000-09-22 2002-04-02 University Of Aarhus Novel compositions and methods for lymphoma and leukemia
CA2451789C (en) 2001-06-29 2012-03-27 Meso Scale Technologies, Llc. Assay plates, reader systems and methods for luminescence test measurements
WO2003068947A1 (en) 2001-07-30 2003-08-21 Meso Scale Technologies, Llc. Assay electrodes having immobilized lipid/protein layers and methods of making and using the same
CA2457775A1 (en) 2001-08-20 2003-02-27 Biosite Incorporated Diagnostic markers of stroke and cerebral injury and methods of use thereof
CA3081228C (en) 2001-09-10 2022-02-15 Meso Scale Technologies, Llc Assay buffer, compositions containing the same, and methods of using the same
WO2003022028A2 (en) 2001-09-10 2003-03-20 Meso Scale Technologies, Llc Methods, reagents, kits and apparatus for protein function analysis
US20070098728A1 (en) * 2001-09-24 2007-05-03 Pedersen Finn S Novel compositions and methods in cancer
WO2003048768A2 (en) 2001-12-05 2003-06-12 Sense Proteomic Limited Protein arrays for allelic variants and uses thereof
AU2003238802A1 (en) * 2002-05-29 2003-12-19 University Of Florida Method and apparatus for detecting and monitoring peptides, and peptides identified therewith
US7036946B1 (en) 2002-09-13 2006-05-02 Rockwell Collins, Inc. LCD backlight with UV light-emitting diodes and planar reactive element
AU2003302263A1 (en) 2002-12-26 2004-07-29 Meso Scale Technologies, Llc. Assay cartridges and methods of using the same
US7981362B2 (en) 2003-11-04 2011-07-19 Meso Scale Technologies, Llc Modular assay plates, reader systems and methods for test measurements
EP1745149A4 (en) 2004-04-15 2008-08-06 Univ Florida NEURALE PROTEINS AS BIOMARKERS FOR INJURY TO THE NERVOUS SYSTEM AND OTHER NEURAL DISORDERS
WO2005121798A1 (en) 2004-06-03 2005-12-22 Meso Scale Technologies, Llc Methods and apparatuses for conducting assays
US20060257943A1 (en) 2005-01-25 2006-11-16 Cis Biotech, Inc. Ischemic biomarkers and their use to predict adverse neurological events from surgery
US7884260B2 (en) 2005-06-14 2011-02-08 University Of Chicago Cell-based screen for agents useful for reducing neuronal demyelination or promoting neuronal remyelination
GB2428240A (en) 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
WO2007123976A2 (en) 2006-04-18 2007-11-01 The Board Of Trustees Of The Leland Stanford Junior University Antibody profiling for determination of patient responsiveness
WO2007136617A2 (en) 2006-05-18 2007-11-29 Walter Reed Army Institute Of Research (Wrair) Endothelial-monocyte activating polypeptide ii, a biomarker for use in diagnosis of brain injury
US8088584B2 (en) 2006-10-16 2012-01-03 Bayer Schering Pharma Aktiengesellschaft LTBP2 as a biomarker and diagnostic target
EP2015196A1 (en) 2007-06-28 2009-01-14 Siemens Aktiengesellschaft Programmer interface for manufacturing execution system
US8497078B2 (en) * 2008-05-23 2013-07-30 The Johns Hopkins University Biomarkers for myocardial ischemia
WO2010019553A2 (en) 2008-08-11 2010-02-18 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
GB201008541D0 (en) 2010-05-21 2010-07-07 Univ Geneve Diagnostic methods
WO2012155134A2 (en) 2011-05-12 2012-11-15 The Johns Hopkins University Assay reagents for a neurogranin diagnostic kit

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008504032A (ja) * 2004-06-25 2008-02-14 ワシントン・ユニバーシティ 脳損傷に対するマーカー

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN6016011920; Ｍｏｌｅｃｕｌａｒ　Ｂｒａｉｎ　Ｒｅｓｅａｒｃｈ，　１９９４，　ｖｏｌ．２７，　ｐｐ．３２３-３２８ *
JPN6016011922; Ｂｒａｉｎ　Ｒｅｓｅａｒｃｈ，　１９９５，　ｖｏｌ．６８５，　ｐｐ．１４３-１５３ *
JPN6016011925; Ｄｅｖｅｌｏｐｍｅｎｔａｌ　Ｎｅｕｒｏｂｉｏｌｏｇｙ，　２００９，　ｖｏｌ．６９，　ｎｏ．２-３，　ｐｐ．１２４-１４０ *
JPN6016011927; Ｂｒａｉｎ　Ｒｅｓｅａｒｃｈ，　２００７，　ｖｏｌ．１１４３，　ｐｐ．７８-８２ *
JPN6016011932; Ｃｌｉｎｉｃａｌ　Ｃｈｅｍｉｓｔｒｙ，　１９９９，　ｖｏｌ．４５，　ｎｏ．９，　ｐｐ．１６２８-１６５０ *
JPN6016011936; Ｂｒａｉｎ　Ｒｅｓｅａｒｃｈ，　２０１０，　ｖｏｌ．１３６２，　ｐｐ．１３-２２ *
JPN6016011939; Ｔｅｃｈｎｏｌｏｇｉｃａｌ　Ｉｎｎｏｖａｔｉｏｎ　ａｎｄ　Ｒｅｓｏｕｒｃｅｓ，　Ｅｐｕｂ　２０１１　Ｆｅｂ　２７． ｖｏｌ．１０，　ｎｏ．６，　Ｍ１１０．００６５９３ *
JPN6016011941; ＡＢ　ＳＣＩＥＸ，　２０１０ ［検索日：２０１６年３月１７日］ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017529527A (ja) * 2014-08-26 2017-10-05 イマビオテクＩｍａｂｉｏｔｅｃｈ 質量分析イメージングによってサンプルを特徴づける方法

Also Published As

Publication number Publication date
WO2012155134A2 (en) 2012-11-15
US20140141458A1 (en) 2014-05-22
WO2012155134A3 (en) 2013-06-13
EP2707389B1 (en) 2019-10-30
EP2707389A4 (en) 2015-08-12
US10215764B2 (en) 2019-02-26
EP2707389A2 (en) 2014-03-19
US9709578B2 (en) 2017-07-18
US20170038397A1 (en) 2017-02-09
US20170315138A1 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
US10215764B2 (en) Assay reagents for a neurogranin diagnostic kit
US10914749B2 (en) Biomarkers of cognitive dysfunction
CN112567246B (zh) 治疗脊髓性肌萎缩症的方法
CA2600168A1 (en) Markers of renal transplant rejection and renal damage
CN111699391A (zh) 用于诊断和评估创伤性脑损伤的新型生物标志物和方法
CN106461681B (zh) 用于诊断血管疾病的生物标志物及其用途
CN105548561B (zh) 阿尔茨海默病的诊断药和诊断方法
AU2019255622B2 (en) Compositions and methods for treating cardiovascular disease in selected patients
JP2010014689A (ja) プロテオミクス解析を用いたメラノーママーカーの同定
TWI465720B (zh) 預測神經發育、神經的或神經精神性病症治療之臨床效益之方法
EP2795337B1 (en) Screening methods to identify compounds useful in the prevention and/or treatment of inflammatory conditions
EP2631656B1 (en) Marker for amyotrophic lateral sclerosis, and use thereof
KR102193393B1 (ko) 신부전 환자에서 신장 이식 거부반응 및 심혈관계 합병증의 진단 또는 예측을 위한 마커로써 엔도칸 및 이의 용도
WO2024107745A1 (en) Methods to detect csf mtbr-tau and uses thereof
Leipp et al. BRAIN COMMUNICATIONS
WO2024040115A2 (en) ANTIBODIES FOR PLATELET FCγRIIA AND RELATED METHODS OF USE
CA3213085A1 (en) Csf phosphorylated tau and amyloid beta profiles as biomarkers of tauopathies
EA050606B1 (ru) Способы лечения спинальной мышечной атрофии
CA3089120A1 (en) Methods of treating spinal muscular atrophy
NZ620075B2 (en) A method for predicting clinical benefit in the treatment of neurodevelopmental, neurological or neuropsychiatric disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150511

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160623

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161128